Foresite Capital Opportunity Management V

Latest statistics and disclosures from Foresite Capital Opportunity Management V's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are PRDS, QSI, THRX, HLTH, CGEM, and represent 81.53% of Foresite Capital Opportunity Management V's stock portfolio.
  • Added to shares of these 1 stocks: ENTA.
  • Started 1 new stock positions in ENTA.
  • Reduced shares in these 2 stocks: HLTH (-$5.7M), CGEM.
  • Foresite Capital Opportunity Management V was a net seller of stock by $-4.6M.
  • Foresite Capital Opportunity Management V has $71M in assets under management (AUM), dropping by -52.12%.
  • Central Index Key (CIK): 0001792207

Tip: Access up to 7 years of quarterly data

Positions held by Foresite Capital Opportunity Management V consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Foresite Capital Opportunity Management V

Companies in the Foresite Capital Opportunity Management V portfolio as of the March 2022 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Pardes Biosciences (PRDS) 52.8 $38M 5.2M 7.22
Quantum-Si Incorporated Com Cl A (QSI) 10.5 $7.5M 1.6M 4.68
Theseus Pharmaceuticals (THRX) 7.6 $5.4M 469k 11.53
Cue Health (HLTH) 5.8 $4.1M -57% 642k 6.45
Cullinan Oncology (CGEM) 4.9 $3.5M -13% 331k 10.47
Adicet Bio (ACET) 4.8 $3.4M 170k 19.97
Gemini Therapeutics (GMTX) 4.7 $3.4M 2.4M 1.39
Kinnate Biopharma (KNTE) 4.6 $3.3M 292k 11.26
Enanta Pharmaceuticals (ENTA) 2.3 $1.6M NEW 23k 71.16
Compass Therapeutics (CMPX) 2.1 $1.5M 1.1M 1.37

Past Filings by Foresite Capital Opportunity Management V

SEC 13F filings are viewable for Foresite Capital Opportunity Management V going back to 2021